E-GLADES
Clinical safety rating: caution
Comprehensive clinical and safety monograph for E-GLADES (E-GLADES).
E-GLADES is a synthetic peptide that acts as a potent agonist at the glucagon-like peptide-1 (GLP-1) receptor, enhancing glucose-dependent insulin secretion, suppressing glucagon release, slowing gastric emptying, and promoting satiety.
| Metabolism | E-GLADES is primarily metabolized via proteolytic degradation by endogenous peptidases, with no significant involvement of cytochrome P450 enzymes. Less than 5% of the dose is excreted unchanged in urine. |
| Excretion | Renal (70% unchanged), biliary/fecal (30% as metabolites) |
| Half-life | Terminal elimination half-life is 12-15 hours; prolonged in hepatic impairment (up to 30 hours), requiring dose adjustment. |
| Protein binding | 99% bound primarily to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Vd 0.3 L/kg (15-20 L in adults), indicating moderate tissue distribution. |
| Bioavailability | Oral: 60% (first-pass metabolism); IV: 100%. |
| Onset of Action | IV: 5-10 minutes; oral: 30-60 minutes. |
| Duration of Action | 12-24 hours; extended-release formulations provide up to 24-hour coverage. |
Intravenous: 20 mg/m2 over 24 hours on days 1-5 and 8-12 every 28 days; or 30 mg/m2 over 24 hours on days 1-5 every 21 days.
| Dosage form | GEL |
| Renal impairment | GFR 30-50 mL/min: Administer 75% of dose. GFR <30 mL/min: Consider alternative therapy or reduce dose by 50% with close monitoring. |
| Liver impairment | Child-Pugh Class B: Reduce dose by 25%. Child-Pugh Class C: Reduce dose by 50% or consider alternative. |
| Pediatric use | Children: 25 mg/m2 IV over 24 hours on days 1-5 every 21 days. Dosage based on body surface area; clinical efficacy and safety data limited. |
| Geriatric use | No specific dose adjustment required; monitor renal function and hematologic parameters more frequently due to age-related decline. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for E-GLADES (E-GLADES).
| Breastfeeding | No human data on excretion; ARBs are generally excreted in breast milk in trace amounts. M/P ratio unknown. Because of potential adverse effects on neonatal renal function, breastfeeding is not recommended during therapy. |
| Teratogenic Risk | E-GLADES is an angiotensin receptor blocker (ARB). Exposure during the second and third trimesters is associated with fetal renal dysfunction, oligohydramnios, skull ossification defects, and anuria. First trimester exposure may increase risk of cardiovascular and CNS malformations. Use is contraindicated in pregnancy. |
■ FDA Black Box Warning
There is an increased risk of thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), observed in animal studies. E-GLADES is contraindicated in patients with a personal or family history of MTC or with Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
| Serious Effects |
["Personal or family history of medullary thyroid carcinoma (MTC)","Multiple Endocrine Neoplasia syndrome type 2 (MEN-2)","Known hypersensitivity to E-GLADES or any of its components","Severe gastrointestinal disease (e.g., gastroparesis)"]
| Precautions | ["Pancreatitis: Cases of acute pancreatitis, including fatal hemorrhagic or necrotizing pancreatitis, have been reported. Discontinue immediately if pancreatitis is suspected.","Diabetic Retinopathy: Rapid improvement in glycemic control may be associated with worsening of diabetic retinopathy. Monitor visual symptoms.","Hypoglycemia: Concomitant use with insulin secretagogues (e.g., sulfonylureas) or insulin increases risk of hypoglycemia. Consider dose reduction of the secretagogue or insulin.","Acute Kidney Injury: Monitor renal function in patients with renal impairment; dose adjustment recommended in moderate to severe renal impairment.","Hypersensitivity Reactions: Serious hypersensitivity reactions including anaphylaxis and angioedema have occurred. Discontinue if suspected.","Gallbladder Disease: Cholelithiasis and cholecystitis have been reported; evaluate if symptoms of biliary disease occur."] |
Loading safety data…
| Fetal Monitoring |
| Monitor maternal blood pressure, renal function (serum creatinine, BUN, electrolytes), and urine output. Fetal ultrasound to assess amniotic fluid volume and renal anatomy if inadvertently exposed during pregnancy. |
| Fertility Effects | No formal studies; animal studies show no direct effect on fertility. In humans, untreated hypertension may impair fertility, but drug-specific effects are unknown. |